UK markets open in 5 hours 59 minutes

Arix Bioscience plc (ARIX.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
176.00-9.00 (-4.86%)
At close: 4:35PM BST
Full screen
Previous close185.00
Open185.00
Bid0.00 x 0
Ask0.00 x 0
Day's range176.00 - 185.00
52-week range73.00 - 234.00
Volume142,911
Avg. volume248,682
Market cap231.653M
Beta (5Y monthly)1.60
PE ratio (TTM)1.98
EPS (TTM)88.70
Earnings date11 Mar 2021 - 12 Mar 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est295.33
  • EQS Group

    Transaction in own shares

    Arix Bioscience PLC (ARIX) 18-Jun-2021 / 17:13 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Arix Bioscience plc Transaction in own shares LONDON, 18 June 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE:ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it purchased the following number of its ordinary share

  • EQS Group

    Results of Annual General Meeting

    Arix Bioscience PLC (ARIX) 14-Jun-2021 / 14:55 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Arix Bioscience Plc Results of Annual General Meeting LONDON, 14 June 2021: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or the "Company"), a global venture capital company focused on investing and building breakthrough biotech companies, today announces that its Annual General Meeting (the "Meeti

  • EQS Group

    Clinical portfolio update

    Arix Bioscience PLC (ARIX) 11-Jun-2021 / 13:05 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Arix Bioscience plc Clinical portfolio update LONDON, 11 June 2021: Arix Bioscience plc ("Arix", LSE:ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes clinical progress in its portfolio companies, Harpoon Therapeutics (Nasdaq: HARP,